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Abstract
Background: Dry eye is a common problem in Ophthalmology and may occur for many reasons including Sjogren’s
syndrome (SS). Recent studies have identified autoantibodies, anti-salivary gland protein 1 (SP1), anti-carbonic anhydrase 6
(CA6) and anti-parotid secretory protein (PSP), which occur early in the course of SS.
The current studies were designed to evaluate how many patients with idiopathic dry eye and no evidence of systemic
diseases from a dry eye practice have these autoantibodies.
Methods: Patients from a dry eye clinic and normal controls were assessed by Schirmer’s test for tear flow.
Sera were assessed for autoantibodies using ELISA assays. Statistics was performed with Prism 7 software and
student’s unpaired t test.
Results: In this study 60% of the dry eye patients expressed one of these autoantibodies. Only 30% expressed one of
the autoantibodies associated with long-standing SS, which are included in the diagnostic criteria for SS, anti-Ro and
anti-La. Patients with disease for less than 2 years and mild dry eyes did not express anti-Ro or anti-La, while 25%
expressed anti-SP1. Similar observations, with smaller numbers, were made when patients had not only dry eye but
also dry mouth.
Conclusions: Antibodies to SP1, CA6 and PSP occur in some patients with idiopathic dry eyes. Further studies will be
needed to determine how many of these patients go on to develop systemic manifestations of SS. Testing for these
autoantibodies may allow early recognition of patients with SS. This will lead to improved management of the patients
and the development of new strategies to maintain normal lacrimal and salivary gland function in patients with SS.
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Background
Dry eyes and their complications are commonly seen in
Ophthalmology practices [1, 2]. Recent studies have dem-
onstrated that Sjogren’s syndrome (SS) is common among
patients with dry eyes and is likely underestimated in this
patient population [3, 4]. Current diagnostic criteria for SS
include serological tests, anti-nuclear antibodies (ANA),
rheumatoid factor (RF), anti-La and anti-Ro [5]. Studies
investigating dry eye patients with SS diagnosed by clinical
criteria note that anti-Ro and anti-La may frequently be
negative [6]. Lip biopsies are then required to make a
diagnosis of SS.
Studies initially utilizing animal models for SS and
various subgroups of SS patients have demonstrated
novel autoantibodies, anti-salivary gland protein 1 (SP1),
anti-carbonic anhydrase 6 (CA6) and anti-parotid
secretory protein (PSP) [7]. In animal models, anti-SP1,
anti-CA6 and anti-PSP are expressed earlier in the
course of the disease than anti-Ro and anti-La. Various
studies have suggested that this may be true in patients
with SS [7, 8].
The current studies were established to investigate the
presence of anti-SP1, anti-CA6 and anti-PSP in a popula-
tion of patients with dry eyes. Patients were classified ac-
cording to the degree of dysfunction noted by
Schirmer’s test. No patients had significant medical
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This was a retrospective study performed on a population
of patients being followed in a Dry Eye Practice (Investigator
SE). All patients were included in the study who lacked
a primary cause for their dry eyes, such as medication
with anti-cholinergic effects, radiation therapy, sarcoid-
osis, hepatitis C, HIV, lymphoma or graft-versus-host
disease. Normal controls were obtained from the gen-
eral population. The Institutional Review Board, SUNY
at Buffalo School of Medicine, approved these studies.
Clinical studies
Schirmer’s tests were performed as previously described
[9]. Tear osmolarity was determined by The TearLab
Osmolarity System following the manufacturer’s instruc-
tion. The serology studies for anti-Ro (IgG), anti-La (IgG),
anti-SP1 (IgG, IgA & IgM), anti-CA6 (IgG, IgA & IgM),
and anti-PSP (IgG, IgA & IgM), were performed at by util-
izing enzyme linked immunosorbent assay (ELISA) at
Immco Diagnostics, Buffalo, NY [10].
Statistics
Statistical analysis was performed using Prism 7 software.
Comparison of various groups was performed using
unpaired student’s t test.
Results
The characteristics of the patients studied are shown in
Table 1. The patients with Schirmer’s tests < 3 mm had a
longer duration of disease than the patients with Schirmer’s
tests 3 mm< SCH< 6 mm, but interestingly both groups
had similar ages. The majority of patients in each group
had only dry eyes, but the presence of dry mouth was
present in similar numbers in each group. Of the patients
with Schirmer’s test < 3 mm, one had rheumatoid arthritis
and one had diabetes and hypertension. Of the patients
with Schirmer’s tests 3 mm< SCH< 6 mm, two had dia-
betes, four had hypertension and two had allergic rhinitis.
The remainder of the patients lacked other significant med-
ical conditions.
Because the use of tear osmolarity has been suggested
as a good indicator for lacrimal gland dysfunction in
early Sjogren’s syndrome [11], we evaluated tear osmolarity
in normal controls and patients with keratoconjunctivitis
sicca. Figure 1 demonstrates that tear osmolarity did not
distinguish these two groups (p = .388). We did not there-
fore use tear osmolarity further in our studies.
The evaluation of autoantibodies in these patients led
to very interesting results. As shown in Fig. 2, the novel
autoantibodies, anti-SP1, anti-CA6 and anti-PSP were
present equally in both groups of patients, those with
Schirmer’s tests 3 mm < SCH < 6 mm and those with
Schirmer’s tests < 3 mm. In the patients with Schirmer’s
tests < 3 mm, the difference between expression of Ro/
La versus SP1/CA6/PSP was not statistically significant
(p = .175). The difference in Ro/La expression (p = .036)
or SP1/CA6/PSP (P < .003) between the patients with
Schirmer’s < 3 mm compared to the normal controls was
significant. When looking at the patients with Schirmer’s
tests 3 mm < SCH < 6 mm, the difference in expression
of SP1/CA6/PSP was greater than the expression of
Ro/L a in the patients (p <. 001) and greater in the patients
than in the normal controls (p = .0001). The difference in
Ro/La expression in these patients was not significantly dif-
ferent than the expression of Ro/La in the normal controls
(p = .93). Anti-Ro and anti-La antibodies were more com-
mon in the sera of patients with less tear production.
Figure 3 demonstrates that similar findings were ob-
served when the analysis included only those patients
with both dry eyes and dry mouth. When comparing the
expression of anti-SP1 with that of anti-CA6 and anti-
PSP a few observations were notable. In patients with
dry eyes and dry mouth and Schirmer’s tests 3 mm <
SCH < 6 mm, anti-SP1 was the dominant autoantibody
while in the patients with Schirmer’s tests < 3 mm, anti-
CA6 was the dominant autoantibody. However, the
numbers were small so that no conclusions can be
drawn from these results. In patients with only dry eyes,
equal numbers of patients express either anti-SP1, anti-
CA6 or anti-PSP with several patients expressing two or
all three of these autoantibodies.
To further evaluate patients with very early disease, we
examined the autoantibody studies in 24 patients in the
cohort who not only had Schirmer’s test 3 mm < SCH <
6 mm, but also had symptomatic dry eyes for less than
2 years. None of these patients had dry mouth. As
shown in Fig. 4, this group did not express anti-Ro or
anti-La. Anti-SP1 antibodies were seen in 25% of the
Table 1 Patient Characteristics
SCH < 3 mm 3 mm< SCH < 6 mm Normal
Number in Group 27 38 35
Age 40 – 95 (mean 67.8) yrs. 44 – 80 (mean 63.8) yrs. 31-93 (mean 57.4 years)
Duration of Dry Eyes 1 – 30 (mean 13) yrs. 0.5 – 10 (mean 4.1) years None
Presence of Dry Mouth 9 patients 8 patients None
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patients. The difference in expression of anti-Ro/anti-La
compared to anti-SP1/anti-PSP/anti-CA6 is statistically
significant (p = .0081).
In animal models of SS, the autoantibodies identified
early in the course of the disease are IgM antibodies [12].
At later stages of the disease, IgA and IgG antibodies are
noted. We therefore examined the isotypes of the anti-SP1,
anti-CA6 and anti-PSP antibodies in the patients evaluated
in these studies. Figure 5a evaluates anti-SP1. There is a
tendency in the patients with Schirmer’s <6 mm to have
more IgM antibodies, but because the numbers are small,
none of the differences seen are statistically significant.
Figure 5b evaluates anti-CA6 antibodies. Patients with
Schirmer’s <3 mm had more IgM anti-CA6 than both
patients with Schirmer’s 3 mm < SCH < 6 mm (p = .02)
and normals (p = .02). With the IgG anti-CA6 both the
Schirmer’s < 3 mm (p = .002) and the Schirmer’s 3 mm
< SCH < 6 mm (p = .02) patients were significantly
greater than the normal controls. The IgA anti-CA6
were similar to the IgM anti-CA6 in that the Schir-
mer’s < 3 mm had more antibody than both the patients
with Schirmer’s 3 mm < SCH < 6 mm (p = .005) and the
normal controls (p = .005). Fig. 5c evaluates anti-PSP
antibodies. In these studies, because of the small num-
bers, the only statistically significant changes were IgM
























Fig. 1 Tear osmolarity studies were done as described in materials and
methods. Data shown are the tear osmolarity in the right and left eye











































Fig. 2 Antibodies to Ro, La, SP1, CA6 and PSP were determined by
ELISA in the sera of patients with idiopathic dry eyes and Schirmer’s
tests < 3 mm (27 patients), Schirmer’s tests < 6 mm (38 patients) or
normal controls (35 patients). Data shown are the percent positive in
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Fig. 3 Antibodies to Ro, La, SP1, CA6 and PSP were determined by
ELISA in the sera of patients with idiopathic dry eyes and dry mouth
with Schirmer’s tests < 3 mm (9 patients), Schirmer’s tests < 6 mm
(10 patients). Data shown are the percent positive in each group for

















































Fig. 4 Antibodies to Ro, La, SP1, CA6 and PSP were determined by
ELISA in the sera of 24 patients with idiopathic dry eyes for less than
2 years and Schirmer’s tests < 6 mm. Data shown are the percent
positive for each of these autoantibodies
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controls (p = .04) and IgA anti-PSP Schirmer’s < 3 mm
versus normals (p = .01). This suggests that even the pa-
tients that are picked up at what would be an early
stage of SS, i.e. without systemic manifestations, have
in fact had their autoimmune eye disease for a long
period of time. Interestingly, patients with Schirmer’s
tests 3 mm < SCH < 6 mm had symptoms of dry eyes
for an average of 4.1 years while those with Schirmer’s
tests <3 mm had symptoms of dry eyes for an average of
13 years. It has been noted in several studies that identifi-
cation of patients with early SS is a major challenge [13].
Discussion
The current studies demonstrate that many patients
with “idiopathic” dry eyes, with or without dry mouth,
have autoantibodies that are seen in patients with early
SS. Some of these patients have autoantibodies included
in the current diagnostic criteria for SS, anti-Ro and
anti-La, while more patients express more recently dis-
covered autoantibodies associated with an early stage of
SS, anti-SP1, anti-CA6 and anti-PSP, without anti-Ro or
anti-La.
Previous studies from an academic Sjogren’s center
demonstrated that many patients referred with a diagnosis
of dry eyes in fact had SS that met full criteria established
by the American College of Rheumatology [4]. Many of
these patients had evidence of systemic manifestations of
SS as well. In the current study, patients were studied
from a private dry eye practice who lacked evidence of
systemic manifestations of SS. These patients were in fact
often self-referred or referred by an Internist for an initial
evaluation. They likely had earlier disease than the pa-
tients referred to a tertiary academic center. Nonetheless,
there was still a significant delay in the evaluation by the
Ophthalmologist relative to the onset of dry eyes as indi-
cated by the clinical history but also by the fact that the
predominant autoantibodies were of the IgG or IgA iso-
type rather than the IgM isotype.
Animal models have demonstrated that the earliest
manifestations of SS are loss of salivary gland function
secondary to involvement of the innate immune system
[7, 12, 14]. Lacrimal gland involvement likely occurs ini-
tially in the same manner, although this has not yet been
studied completely. At this stage, antibodies anti-SP1,
anti-CA6 and anti-PSP are noted. In the next stage
lymphocytic infiltration of the glands occurs followed by
progression from a local disease to a systemic disease, with
lung and kidney involvement. Antibodies anti-Ro and
anti-La are identified in the animals at the point when the
disease goes from being local to being systemic [7]. It
should be noted, however, that one study demonstrated
anti-Ro and anti-La antibodies in the sera of patients who
developed SS years before clinical expression of their dis-
ease [15, 16]. So, in some cases, anti-Ro and anti-La may
occur in early disease as well. The challenge from a thera-
peutic point of view is to identify the SS patients at the
very earliest stages, before there has been permanent dam-
age to the lacrimal and salivary glands [17–19]. In animal
models, treatment at this stage can lead to halting of the
disease process [20–22]. The current studies suggest that
















































































Fig. 5 a IgM, IgG and IgA autoantibodies to SP1 were determined by
ELISA in the sera of patients with idiopathic dry eyes and Schirmer’s
tests < 3 mm (27 patients), Schirmer’s tests < 6 mm (38 patients) or
normal controls (35 patients). Data shown are the percent positive in
each group for each of these autoantibodies. b IgM, IgG and IgA
autoantibodies to CA6 were determined by ELISA in the sera of patients
with idiopathic dry eyes and Schirmer’s tests < 3 mm (27 patients),
Schirmer’s tests < 6 mm (38 patients) or normal controls (35 patients).
Data shown are the percent positive in each group for each of these
autoantibodies. c IgM, IgG and IgA autoantibodies to PSP were
determined by ELISA in the sera of patients with idiopathic dry eyes and
Schirmer’s tests < 3 mm (27 patients), Schirmer’s tests < 6 mm (38
patients) or normal controls (35 patients). Data shown are the percent
positive in each group for each of these autoantibodies
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of SS. Perhaps with greater vigilance in the medical com-
munity, Ophthalmologists can see these patients at even
earlier stages.
At the same time, many of the patients in this study had
dry eyes for longer than 10 years without the development
of systemic symptoms. They had autoantibodies consistent
with immune mediated lacrimal gland injury. Perhaps
many patients develop a form of SS that involves only the
lacrimal and/or salivary glands without ever progressing
to more systemic manifestations. These patients would
not meet the accepted criteria for SS, but in fact may de-
serve the same type of immunomodulatory therapy. This
therapy could theoretically be given locally under these
circumstances rather than systemically. Further study will
be necessary to address these issues.
In conclusion, many patients with “idiopathic dry eyes”
identified in a private dry eyes practice have evidence of
immune mediated lacrimal gland injury with serum
autoantibodies consistent with early SS. The criteria for
SS may have to change to accommodate these patients.
Future studies will be necessary to determine the most
appropriate therapies for these patients.
Conclusions
The current studies demonstrate that many patients
with idiopathic dry eyes with or with out dry mouth
have markers for early Sjogren’s syndrome, anti-SP1,
anti-CA6 and anti-PSP. Further study will be necessary
to assess antibody positive patients for various features
of SS over a long period of time and to develop therapies
appropriate for patients showing evidence of early SS.
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